Nuvectis Pharma's Bold Pivot: NXP800 Exits Ovarian Cancer, NXP900 Leads New Oncology Frontier

Discover Nuvectis Pharma's strategic decision to discontinue NXP800 in ovarian cancer after early trial results. Uncover their renewed focus on NXP900 and the broader implications for platinum-resistant therapies and future cancer drug development in a competitive market